115 related articles for article (PubMed ID: 27798858)
21. Gene expression signatures of primary and metastatic uterine leiomyosarcoma.
Davidson B; Abeler VM; Førsund M; Holth A; Yang Y; Kobayashi Y; Chen L; Kristensen GB; Shih IeM; Wang TL
Hum Pathol; 2014 Apr; 45(4):691-700. PubMed ID: 24485798
[TBL] [Abstract][Full Text] [Related]
22. Uterine leiomyosarcoma: a review article.
Gockley AA; Rauh-Hain JA; del Carmen MG
Int J Gynecol Cancer; 2014 Nov; 24(9):1538-42. PubMed ID: 25304676
[TBL] [Abstract][Full Text] [Related]
23. Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma.
Garcia N; Ulin M; Yang Q; Ali M; Bosland MC; Zeng W; Chen L; Al-Hendy A
Cells; 2023 Dec; 12(24):. PubMed ID: 38132150
[TBL] [Abstract][Full Text] [Related]
24. Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms.
Parra-Herran C; Schoolmeester JK; Yuan L; Dal Cin P; Fletcher CD; Quade BJ; Nucci MR
Am J Surg Pathol; 2016 Mar; 40(3):285-301. PubMed ID: 26866354
[TBL] [Abstract][Full Text] [Related]
25. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.
Dinh TA; Oliva EA; Fuller AF; Lee H; Goodman A
Gynecol Oncol; 2004 Feb; 92(2):648-52. PubMed ID: 14766261
[TBL] [Abstract][Full Text] [Related]
26. PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer.
Park JE; Ao L; Miller Z; Kim K; Wu Y; Jang ER; Lee EY; Kim KB; Lee W
PLoS One; 2013; 8(9):e73732. PubMed ID: 24040045
[TBL] [Abstract][Full Text] [Related]
27. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
28. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
29. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
30. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
31. Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Nagase S; Ishiko O; Shiozawa T; Kanai Y; Yaegashi N; Aburatani H; Tonegawa S; Konishi I
N Am J Med Sci; 2011 Sep; 3(9):394-9. PubMed ID: 22362447
[TBL] [Abstract][Full Text] [Related]
32. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
[TBL] [Abstract][Full Text] [Related]
33. Literature review of outcomes and prevalence and case report of leiomyosarcomas and non-typical uterine smooth muscle leiomyoma tumors treated with uterine artery embolization.
Kainsbak J; Hansen ES; Dueholm M
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():130-7. PubMed ID: 26117442
[TBL] [Abstract][Full Text] [Related]
34. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.
Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD
Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924
[TBL] [Abstract][Full Text] [Related]
35. Myocardin functions as an effective inducer of growth arrest and differentiation in human uterine leiomyosarcoma cells.
Kimura Y; Morita T; Hayashi K; Miki T; Sobue K
Cancer Res; 2010 Jan; 70(2):501-11. PubMed ID: 20068148
[TBL] [Abstract][Full Text] [Related]
36. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
[TBL] [Abstract][Full Text] [Related]
37. Recent developments in uterine mesenchymal neoplasms.
Chiang S; Oliva E
Histopathology; 2013 Jan; 62(1):124-37. PubMed ID: 23240674
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
[TBL] [Abstract][Full Text] [Related]
39. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features.
Christacos NC; Quade BJ; Dal Cin P; Morton CC
Genes Chromosomes Cancer; 2006 Mar; 45(3):304-12. PubMed ID: 16320247
[TBL] [Abstract][Full Text] [Related]
40. Uterine Leiomyosarcoma With Osteoclast-like Giant Cells: Report of 2 Cases and Review of Literature.
Chen Z; Ji J; Yung E; Martin SE; Walia S
Int J Gynecol Pathol; 2024 Mar; 43(2):182-189. PubMed ID: 37406452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
